Key result
Loss of heterozygosity at 17p13 was found in 74% of adrenocortical carcinomas compared with 14% of adrenocortical adenomas, with ACADVL and ALOX15B expression significantly down-regulated in ACCs.
Observational
Answers are grounded in this paper and cite their sources.
ACADVL and ALOX15B expression levels on 17p13 may serve as molecular discriminators between adrenocortical carcinomas and adenomas.
OBJECTIVE: To determine the minimal common region of loss on 17p13 in a cohort of adrenocortical carcinomas (ACCs) (defined by a Weiss score > or =3) and adrenocortical adenomas (ACAs) (defined by a Weiss score <3) and subsequently to assess 3 genes in this region that could be involved in adrenocortical tumorigenesis. SUMMARY BACKGROUND DATA: Loss of heterozygosity (LOH) of 17p13 has been demonstrated to occur more frequently in ACCs compared with ACAs. METHODS: Using 12 microsatellite markers across 17p13, LOH analysis was performed on 37 paired blood and adrenocortical tumor samples (23 ACC and 14 ACA samples) to determine the minimal common region of loss for ACCs and ACAs. From this minimal region of loss, 3 genes were selected for quantitative real time reverse transcription polymerase chain reaction analysis on 20 ACCs and 30 ACAs. RESULTS: LOH at 17p13 was found in 74% of ACCs compared with 14% of ACAs. There was a 10.4-Mb common minimal region of loss in ACCs whereas no minimal region of loss in ACAs could be demonstrated. Expression of Acyl coenzyme-A dehydrogenase very long chain (ACADVL) and Arachidonate 15-lipoxygenase second type (ALOX15B) was significantly down-regulated in ACCs compared with ACAs whereas there was no difference in expression of Potassium channel tetramerization domain containing 11 (KCTD11) in ACCs and ACAs. CONCLUSIONS: We demonstrated a minimal common region of loss of 10.4-Mb on 17p13 in ACCs and within this region, we found that ACADVL and ALOX15B expression are good discriminators between ACCs and ACAs.
No takes yet. Share an insight, caveat, or question.
Soon et al. (2008) conducted an observational in Adrenocortical tumors. Adrenocortical carcinoma vs. Adrenocortical adenoma was evaluated on Loss of heterozygosity (LOH) at 17p13. Loss of heterozygosity at 17p13 was found in 74% of adrenocortical carcinomas compared with 14% of adrenocortical adenomas, with ACADVL and ALOX15B expression significantly down-regulated in ACCs.
Synapse has enriched 10 related papers. Consider them for comparative context: